Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer

Pancreas

Volumn 36, Issue 2, 2008, Pages 173-177

  Warnecke Eberz, Ute ^a   Prenzel, Klaus L ^a   Baldus, Stephan E ^b   Metzger, Ralf ^a   Dienes, Hans P ^c   Bollschweiler, Elfriede ^a   Hoelscher, Arnulf H ^a   Schneider, Paul M ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Institute of Pathology   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Gene expression; Plasminogen activator; Plasminogen activator receptor; Quantitative RT PCR; Serpin

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; SERPINE1 PROTEIN, HUMAN; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; VATER PAPILLA CARCINOMA; ADENOCARCINOMA; BILE DUCT TUMOR; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; VATER PAPILLA;

ADENOCARCINOMA; ADULT; AGED; AMPULLA OF VATER; COMMON BILE DUCT NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY PLASMINOGEN ACTIVATOR;

EID: 45549085544     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31815ac538     Document Type: Article

References (43)

1. Jemal A, Murray T, Samuels A, et al. J Cancer Statistics 2003. CA Cancer J Clin. 2003;53:5-26.
2. Fernandez E, La Vecchia C, Porta M, et al. Trends in pancreatic cancer mortality in Europe, 1955-1989. Int J Cancer. 1994;57:786-792.
3. Bramhall SDJ, Neoptolemos JP. Epidemiology of Pancreatic Cancer. Vol 2. Boston, MA: Blackwell Scientific; 1998:889-906.
4. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications and outcomes. Ann Surg. 1997;226:248-257.
5. Hawes RH, Xiong Q, Waxman I, et al. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol. 2000;95:17-31.
6. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995;82: 111-115.
7. Sener F, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1990; 189:1-7.
8. Magee CJ, Greenhalf W, Howes N, et al. Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. Surg Oncol. 2001;10:1-23.
9. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics 2001. CA Cancer J Clin. 2001;51:15-36.
10. Neoptolemos JP, Dunn JA, Stocken DD, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPACY1 randomized controlled trial. Ann Surg. 2001;234:758-768.
11. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreasV616 patients: results, outcomes, and prognostic indicators. J Gastrointestinal Surg. 2000;4:567-579.
12. Beger HG, Treitschke F, Poch B. Adenocarcinoma of the ampulla of VaterVoperative treatments and results. In: Beger HG, Warshaw Al, Büchler MW, et al, eds. The Pancreas. Oxford, UK: Blackwell Science; 1998:1328-1331.
13. Willett CG, Warshaw AL, Convery K, et al. Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet. 1993;176:33-38.
14. Prenzel KL, Warnecke-Eberz U, Brabender J, et al. Differential cYerbBY1 and cYerbBY2 expression in pancreatic and ampullary cancer. World J Gastroenterol. 2006;12:437-442.
15. Prenzel KL, WarneckeYEberz U, Xi H, et al. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncol Rep. 2006;15: 1397-1401.
16. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932-943.
17. Andreasen PA, Kjoller L, Christensen L, et al. The urokinaseYtype plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
18. Choong PFM, Orth FA, Anne OW. Urokinase plasminogen activator system. Clin Orthop Relat Res. 2003;425S:46-58.
19. Dano K, Behrendt N, Hoyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost. 2005;93:676-681.
20. Buchholz M, Biebl A, Albrecht N, et al. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 2003;63:4945-4951.
21. Warnecke-Eberz U, Metzger R, Miyazono F, et al. High specificity of quantitative excision repair crossYcomplementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res. 2004;10:3794-3799.
22. Warnecke-Eberz U, Hokita S, Xi H, et al. Overexpression of survivin mRNA is associated with a favourable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep. 2005;13: 1241-1246.
23. LeBlanc M, Jacobson J, Crowley J. Partitioning and peeling for constructing prognostic groups. Stat Methods Med Res. 2002;11: 247-274.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:187-220.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Chemother Rep. 1966;50:163-170.
26. Heaton JH, Dlakic WM, Gelehrter TD. Posttranscriptional regulation of PAIY1 gene expression. Thromb Haemost. 2003;89:959-966.
27. Dellas C, Loskutoff DJ. Historical analysis of PAIY1 from its discovery to its potential role in cell motility and disease. Thromb Haemost. 2005;93:631-640.
28. Guo Y, Higazi AA, Arakelian A, et al. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 2000;14:1400-1410.
29. Kobayashi H, Gotoh J, Fujie M, et al. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factorYlike domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer. 1994;57:727-733.
30. Magdolen V, Kruger A, Sato S, et al. Inhibition of the tumorYassociated urokinaseYtype plasminogen activation system: effects of highYlevel synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Recent Results Cancer Res. 2003;162: 43-63.
31. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen target for therapy. Thromb Haemost. 1997;78:285-296.
32. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinaseYtype plasminogen activator and its inhibitor PAIY1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116-128.
33. Bouchet C, Ferrero-Pous M, Hacène K, et al. Limited prognostic value of cYerbBY2 compared to uPA and PAIY1 in primary breast carcinoma. Int J Biol Markers. 2003;18:207-217.
34. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst. 1999;91:869-874.
35. Nielsen HJ, Pappot H, Christensen J, et al. Association between plasma concentrations of plasminogen activator inhibitorY1 and survival in patients with colorectal cancer. BMJ. 1998;316:829-830.
36. Kuhn W, Pache L, Schmalfeldt B, et al. Urokinase (uPA) and PAIY1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinumYbased chemotherapy. Gynecol Oncol. 1994;55:401-409.
37. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinaseYtype plasminogen activator and its inhibitor PAIYI in completely resected gastric cancer. Cancer Res. 1994;54:2900-2929.
38. Soff GA, Sanderowitz J, Gately S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumorYassociated angiogenesis and metastasis to lung and liver in an athymic mouse model. J Clin Invest. 1995;96: 2593-2600.
39. Cajot JF, Bamat J, Bergonzelli GE, et al. Plasminogen activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A. 1990;87:6939-6943.
40. Alizadet H, Ma D, Berman M, et al. TissueYtype plasminogen activatorYinduced invasion and metastasis of murine melanomas. Curr Eye Res. 1995;14:449-458.
41. Inoue M, Sawada T, Uchima Y, et al. Plasminogen activator inhibitorY1 (PAIY1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis. Oncol Rep. 2005;14:1445-1451.
42. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem. 2004;37:541-548.
43. Luebke T, Baldus SE, Spieker D, et al. Is the urokinaseYtype plasminogen activator system a reliable prognostic factor in gastric cancer? Int J Biol Markers. 2006;21:162-169.